S. Rennard (Omaha, United States of America), E. Russi (Zurich, Switzerland)
Guidelines for nebulizer prescription - how useful in practice
S. Aparna, S. R. Nair, S. B. Pearson (Leeds, United Kingdom)
|  |
Use of dry powder inhalers in COPD
J. Rees, D. Wilson, M. Gillion (London, United Kingdom)
| |
Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV)
J. Munoz, I. Alfageme, N. Reyes, J. Perez, M. Merino, F. Gonzalez, F. Saez, P. Martin (Madrid, Seville, Spain)
| |
Effectiveness of transdermal tulbuterol in the management of stable COPD
Y. Fukuchi, K. Seyama, M. Nishimura, K. Hirata, BAREC Research Group (Tokyo, Sapporo, Osaka, Japan)
| |
Ipratropium bromide effects on intraocular pressure in COPD patients
D. Vidanovic, G. Vidanovic, M. Zivanovic (Sokobanja, Serbia And Montenegro)
| |
Budesonide/formoterol is a well-tolerated long term maintenance therapy for COPD
P. M. Calverley, W. Szafranski, A. Andersson (Liverpool, United Kingdom; Radom, Poland; Lund, Sweden)
| |
Does the degree of oxygen desaturation during exercise affect the response to ambulatory oxygen in COPD?
A. Cukier, R. Stelmach, F. Cortopassi, M. Ribeiro, C. Ferreira, P. M. Calverley (Sao Paulo, Brazil; Liverpool, United Kingdom)
| |
A phase 1B/2A study to evaluate the effect of aerosolized, recombinant alpha 1-antitrypsin (rAAT) on epithelial lining fluid (ELF) analytes in subjects with AAT deficiency
D. Gelmont, D. Sundin, K. Chung (Westlake Village, Alameda, United States Of America)
| |
Indacaterol, a novel 24-hour β2-agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD
M. Aubier, X. Duval, H. Knight, S. Perry, J. Wood, L. Brookman (Paris, France; Horsham, United Kingdom)
| |
Augmentation therapy for α1-antitrypsin deficiency: a meta-analysis of randomized and non-randomized clinical studies
K. R. Chapman, R. A. Stockley, C. Dawkins, M. M. Wilkes, R. J. Navickis (Toronto, Canada; Birmingham, United Kingdom; Grass Valley, United States Of America)
| |
Response of lung volumes in chronic obstructive pulmonary disease patients with improvement of airflow limitation
W. I. Choi, Y. J. Jeon, S. H. Park, M. Y. Lee (Daegu, Republic Of Korea)
| |
Diagnosis of COPD combined with brief smoking cessation advice increases smoking cessation rate in comparison with those with normal lung function
G. Stratelis, S. Molstad, P. Jakobsson, O. Zetterstrom (Motala, Jonkoping, Linkoping, Sweden)
| |
Lung volume reduction surgery in COPD: pathologic discrepancies
A. Cherniaev, A. Cherniak, D. Bazarov, V. Parshin, J. Naumenko (Moscow, Russian Federation)
| |
Sertraline effects on dyspnea in patients with severe COPD
L. Lores, M. Palau, F. Andreo, X. Casas, C. Plans (Sant Boi, Viladecans, Spain)
| |
Quality of life in patients with COPD and nocturnal supplemental oxygen-therapy: a prospective, placebo-controlled cross-over trial
J. W. Walther, H. W. Duchna, T. T. Bauer, S. Yalzin, J. de Zeeuw, S. Kotterba, G. Schultze-Werninghaus, H. T. Baberg, K. Rasche, M. Orth (Bochum, Wuppertal, Germany)
| |
Determinants for the reversibility of airflow limitation in COPD
Y. Nasuhara, H. Makita, N. Hizawa, T. Betsuyaku, M. Nishimura, and the Hokkaido COPD Cohort Study Group (Sapporo, Japan)
| |
Cardiac safety of formoterol in COPD
S. Campbell, G. Criner, B. Ziehmer, C. Orevillo, J. Smith (Tucson, Philadelphia, East Hanover, United States Of America; Horsham, United Kingdom)
| |
Effects of tiotropium bromide in exercise tolerance in patients with chronic obstructive pulmonary disease
A. Baloira, C. Vilarino (Pontevedra, Spain)
| |
Evaluation of tiotropium rotacaps once daily in patients with chronic obstructive pulmonary disease over 4 weeks
J. Joshi, V. Singh, K. Jagannath, A. Athavale, J. Po, J. Gogtay (Mumbai, Jaipur, Chennai, India)
| |
Budesonide/formoterol improves the wellbeing of patients with COPD: results from a real-life setting
C. R. Silva, P. Kawage, W. G. Filho, U. Nihlen, E. Ståhl (Sao Paulo, Brazil; Lund, Sweden)
| |